NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces it will be offering special promotions and discounts on its Avenova®-branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month.

National Dry Eye Awareness Month is intended to recognize the importance of eye health to overall health, and to educate the public about dry eye. The Sj�gren's Foundation and its partners first asked Congress to declare July as Dry Eye Awareness Month in 2005. Prevent Blindness also recognizes July as Dry Eye Awareness Month. Dry eye disease is a multifactorial disease that affects an estimated 25 million people in the U.S., and is often a condition that is under-recognized and under-diagnosed.

“We are excited to support a month-long effort to focus attention on a condition that affects millions of Americans,” said Justin Hall, NovaBay CEO. “In appreciation of customers who recognize the importance of a consistent, comprehensive dry eye regimen, throughout July we will be promoting our subscribe and save offering on Amazon.com and Avenova.com, which features a 15% price discount and free shipping. This discount extends to product bundles such as our Dry Eye Essentials and Total Eye Health that include an array of daily essentials specifically designed to provide individualized relief from dry eye symptoms.

“In addition, during July we are featuring special Avenova offers to eyecare professionals who specialize in the treatment of dry eye, specifically targeting new customers and existing customers with high-volume orders who use intense pulsed light (IPL) and thermal pulsation to treat symptoms caused by blepharitis and meibomian gland dysfunction,” he added. “By providing ongoing maintenance and enhancing overall treatment benefits, Avenova spray – formulated with our patented, proprietary, stable and pure hypochlorous acid – is highly complementary to these procedures.”

NovaBay offers best-in-class Avenova-branded products for each step of the standard dry-eye treatment regimen, including Avenova spray, the No. 1 doctor-recommended hypochlorous acid lid and lash cleanser, lubricating eye drops for instant relief, a warm eye compress to soothe, an antioxidant-rich dietary supplement with omega-3 oils and the i-Chek to monitor eyelid health. Avenova products are available directly to consumers through online distribution channels such as Amazon.com and Avenova.com.

About NovaBay Pharmaceuticals, Inc.

NovaBay’s leading product Avenova® Antimicrobial Lid & Lash Solution is often prescribed by eyecare professionals for blepharitis and dry eye disease. Manufactured in the U.S., it is clinically proven to kill a broad spectrum of bacteria to help relieve the symptoms of bacterial dry eye, yet is non-irritating and completely safe for regular use. In addition to the Avenova OTC product line, NovaBay offers the Avenova Allograft, an amniotic tissue prescription-only product available through eyecare professionals nationwide.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our current revenue sources, expected future revenue, customer satisfaction, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, and revenues will not be sufficient to meet the Company’s cash needs. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and stay informed on NovaBay’s progress Like us on Facebook Follow us on X Connect with NovaBay on LinkedIn Visit NovaBay's Website

Avenova Purchasing Information For NovaBay Avenova purchasing information: Please call 800-890-0329 or email sales@avenova.com Avenova.com

NovaBay Contact Justin Hall Chief Executive Officer and General Counsel 510-899-8800 jhall@novabay.com Investor Contact LHA Investor Relations Jody Cain 310-691-7100 jcain@lhai.com

Grafico Azioni NovaBay Pharmaceuticals (AMEX:NBY)
Storico
Da Gen 2025 a Feb 2025 Clicca qui per i Grafici di NovaBay Pharmaceuticals
Grafico Azioni NovaBay Pharmaceuticals (AMEX:NBY)
Storico
Da Feb 2024 a Feb 2025 Clicca qui per i Grafici di NovaBay Pharmaceuticals